Related Experiment Videos
Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy
Laura J Pinderski1, Gregg C Fonarow, Michele Hamilton
1Division of Cardiology, UCLA Medical Center, Los Angeles, California, USA. lpinder@uab.edu
Insights
Giant cell myocarditis (GCM) is a rare heart condition. This case study shows that T-cell targeted immunosuppression, alongside mechanical support, can successfully treat severe GCM.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Giant cell myocarditis (GCM) is a rare and aggressive form of heart muscle inflammation.
- Rapidly decompensating heart failure presents a significant clinical challenge.
Observation:
- A 40-year-old male presented with acute, severe heart failure.
- Endomyocardial biopsy confirmed the diagnosis of giant cell myocarditis.
Findings:
- The patient's condition improved with biventricular assist device support and myocardial rest.
- Immunosuppressive therapy, including OKT3 (anti-T cell therapy) and high-dose steroids, was crucial for recovery.
- The patient was successfully weaned from mechanical support and discharged.
Implications:
- T-lymphocytic cytolytic therapy, such as OKT3, may represent a promising treatment strategy for GCM.
- Further clinical studies are warranted to validate the efficacy of T-cell targeted therapies in GCM management.
- This case highlights the potential benefit of combining mechanical circulatory support with targeted immunosuppression.
Abstract:
We describe a case of a 40-year-old man who presented with recent-onset, rapidly decompensating heart failure, and who was found to have giant cell myocarditis (GCM) on biopsy. The patient responded to myocardial rest on a biventricular assist device, as well as immunosuppression that included eradication of T cells using OKT3 therapy, coupled with high-dose steroids. The patient was successfully weaned off mechanical support, and ultimately discharged home, where he continues to do well. Based on a review of the clinical and experimental literature, we believe treatment with T-lymphocytic cytolytic therapy may be beneficial. Further studies using this therapy in the treatment of GCM are warranted.